647 related articles for article (PubMed ID: 18828174)
1. Engineering cell lines for production of replication defective HSV-1 gene therapy vectors.
Grant KG; Krisky DM; Ataai MM; Glorioso JC
Biotechnol Bioeng; 2009 Mar; 102(4):1087-97. PubMed ID: 18828174
[TBL] [Abstract][Full Text] [Related]
2. HSV-1 infected cell proteins influence tetracycline-regulated transgene expression.
Herrlinger U; Pechan PA; Jacobs AH; Woiciechowski C; Rainov NG; Fraefel C; Paulus W; Reeves SA
J Gene Med; 2000; 2(5):379-89. PubMed ID: 11045432
[TBL] [Abstract][Full Text] [Related]
3. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons.
Krisky DM; Wolfe D; Goins WF; Marconi PC; Ramakrishnan R; Mata M; Rouse RJ; Fink DJ; Glorioso JC
Gene Ther; 1998 Dec; 5(12):1593-603. PubMed ID: 10023438
[TBL] [Abstract][Full Text] [Related]
4. Inducible gene expression of the human immunodeficiency virus LTR in a replication-incompetent herpes simplex virus vector.
Warden MP; Weir JP
Virology; 1996 Dec; 226(1):127-31. PubMed ID: 8941330
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of genomic HSV vectors for gene delivery to motor neurons following peripheral inoculation in vivo.
Perez MC; Hunt SP; Coffin RS; Palmer JA
Gene Ther; 2004 Jul; 11(13):1023-32. PubMed ID: 15164091
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
7. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
[TBL] [Abstract][Full Text] [Related]
8. The role of ICP4 repressor activity in temporal expression of the IE-3 and latency-associated transcript promoters during HSV-1 infection.
Rivera-Gonzalez R; Imbalzano AN; Gu B; Deluca NA
Virology; 1994 Aug; 202(2):550-64. PubMed ID: 8030221
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of infection parameters in the production of replication-defective HSV-1 viral vectors.
Ozuer A; Wechuck JB; Russell B; Wolfe D; Goins WF; Glorioso JC; Ataai MM
Biotechnol Prog; 2002; 18(3):476-82. PubMed ID: 12052062
[TBL] [Abstract][Full Text] [Related]
10. Highly efficient regulation of gene expression by tetracycline in a replication-defective herpes simplex viral vector.
Yao F; Theopold C; Hoeller D; Bleiziffer O; Lu Z
Mol Ther; 2006 Jun; 13(6):1133-41. PubMed ID: 16574491
[TBL] [Abstract][Full Text] [Related]
11. An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells.
Lee CY; Bu LX; Rennie PS; Jia WW
Cancer Gene Ther; 2007 Jul; 14(7):652-60. PubMed ID: 17479106
[TBL] [Abstract][Full Text] [Related]
12. Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications.
Krisky DM; Marconi PC; Oligino TJ; Rouse RJ; Fink DJ; Cohen JB; Watkins SC; Glorioso JC
Gene Ther; 1998 Nov; 5(11):1517-30. PubMed ID: 9930305
[TBL] [Abstract][Full Text] [Related]
13. Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector.
Watanabe D; Brockman MA; Ndung'u T; Mathews L; Lucas WT; Murphy CG; Felber BK; Pavlakis GN; Deluca NA; Knipe DM
Virology; 2007 Jan; 357(2):186-98. PubMed ID: 16996101
[TBL] [Abstract][Full Text] [Related]
14. ICP0, ICP4, or VP16 expressed from adenovirus vectors induces reactivation of latent herpes simplex virus type 1 in primary cultures of latently infected trigeminal ganglion cells.
Halford WP; Kemp CD; Isler JA; Davido DJ; Schaffer PA
J Virol; 2001 Jul; 75(13):6143-53. PubMed ID: 11390616
[TBL] [Abstract][Full Text] [Related]
15. Latency associated promoter transgene expression in the central nervous system after stereotaxic delivery of replication-defective HSV-1-based vectors.
Scarpini CG; May J; Lachmann RH; Preston CM; Dunnett SB; Torres EM; Efstathiou S
Gene Ther; 2001 Jul; 8(14):1057-71. PubMed ID: 11526453
[TBL] [Abstract][Full Text] [Related]
16. Replication-Competent Controlled Herpes Simplex Virus.
Bloom DC; Feller J; McAnany P; Vilaboa N; Voellmy R
J Virol; 2015 Oct; 89(20):10668-79. PubMed ID: 26269179
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus 1 ICP27 is required for transcription of two viral late (gamma 2) genes in infected cells.
Jean S; LeVan KM; Song B; Levine M; Knipe DM
Virology; 2001 May; 283(2):273-84. PubMed ID: 11336552
[TBL] [Abstract][Full Text] [Related]
18. The herpes simplex virus immediate-early protein ICP27 shuttles between nucleus and cytoplasm.
Mears WE; Rice SA
Virology; 1998 Mar; 242(1):128-37. PubMed ID: 9501050
[TBL] [Abstract][Full Text] [Related]
19. Characterization of regulatory functions of the HSV-1 immediate-early protein ICP22.
Prod'hon C; Machuca I; Berthomme H; Epstein A; Jacquemont B
Virology; 1996 Dec; 226(2):393-402. PubMed ID: 8955059
[TBL] [Abstract][Full Text] [Related]
20. Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo.
Lilley CE; Groutsi F; Han Z; Palmer JA; Anderson PN; Latchman DS; Coffin RS
J Virol; 2001 May; 75(9):4343-56. PubMed ID: 11287583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
